Chen Kai-Yang, Chan Hoi-Chun, Chan Chi-Ming
School of Medicine, College of Medicine, Taipei Medical University, Taipei.
School of Pharmacy, China Medical University, Taichung.
J Refract Surg. 2025 Aug;41(8):e839-e854. doi: 10.3928/1081597X-20250506-07. Epub 2025 Aug 1.
To evaluate the effectiveness of keratorefractive lenticule extraction (KLEx) in providing superior ocular surface protection compared to femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK), focusing on key dry eye parameters such as tear break-up time (TBUT), Ocular Surface Disease Index (OSDI), Schirmer test, and corneal sensitivity.
A systematic search was conducted in PubMed, Scopus, Web of Science, and Embase in December 2024, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Inclusion criteria required human studies comparing KLEx (small incision lenticule extraction [SMILE]) and FS-LASIK with outcomes related to TBUT, OSDI, Schirmer test, and corneal sensitivity. Statistical analysis was performed using RevMan 5.3, employing a random-effects model to account for clinical heterogeneity. Heterogeneity was evaluated using Higgins' I statistic, and publication bias was assessed through funnel plots.
This meta-analysis, including 18 studies, compared KLEx (SMILE) and FS-LASIK in terms of dry eye parameters. The findings indicate that KLEx provides superior tear film stability, with significantly longer TBUT at 3 months (MD = 3.267 sec, < .0001) and 6 months (MD = 3.320 sec, < .0001). OSDI scores were slightly lower for KLEx, but the difference was not statistically significant. Schirmer test results (MD = 0.820 mm, = .0001) favored KLEx, suggesting better tear production. KLEx also demonstrated better corneal sensitivity preservation, with significant differences at 1 (MD = 18.48, < .0001) and 6 (MD = 7.56, = .02) months, indicating less nerve damage. Sensitivity analyses confirmed the reliability of these findings. These results suggest that KLEx may be the preferable option for patients at risk of postoperative dry eye disease, offering better ocular surface stability and faster recovery.
KLEx offers significant advantages over FS-LASIK in TBUT and corneal sensitivity, indicating better tear film stability and nerve preservation. Both procedures yielded similar results for OSDI and Schirmer test outcomes. These findings suggest that KLEx may be a preferable option for patients at higher risk of postoperative dry eye disease. Future research should focus on standardized protocols and long-term follow-up to strengthen these conclusions.
与飞秒激光制瓣准分子原位角膜磨镶术(FS-LASIK)相比,评估角膜屈光透镜切除术(KLEx)在提供更好的眼表保护方面的有效性,重点关注关键干眼参数,如泪膜破裂时间(TBUT)、眼表疾病指数(OSDI)、泪液分泌试验和角膜敏感性。
2024年12月,按照系统评价和Meta分析的首选报告项目(PRISMA)指南,在PubMed、Scopus、科学网和Embase中进行了系统检索。纳入标准要求是比较KLEx(小切口透镜切除术[SMILE])和FS-LASIK且结果与TBUT、OSDI、泪液分泌试验和角膜敏感性相关的人体研究。使用RevMan 5.3进行统计分析,采用随机效应模型来考虑临床异质性。使用希金斯I统计量评估异质性,并通过漏斗图评估发表偏倚。
这项包括18项研究的Meta分析比较了KLEx(SMILE)和FS-LASIK在干眼参数方面的情况。研究结果表明,KLEx能提供更好的泪膜稳定性,在3个月时TBUT显著更长(MD = 3.267秒,P <.0001),6个月时也是如此(MD = 3.320秒,P <.0001)。KLEx的OSDI评分略低,但差异无统计学意义。泪液分泌试验结果(MD = 0.820毫米,P =.0001)支持KLEx,表明泪液分泌更好。KLEx在角膜敏感性保留方面也表现更好,在1个月(MD = 18.48,P <.0001)和6个月(MD = 7.56,P =.02)时有显著差异,表明神经损伤更少。敏感性分析证实了这些结果的可靠性。这些结果表明,对于有术后干眼疾病风险的患者,KLEx可能是更优选择,能提供更好的眼表稳定性和更快的恢复。
在TBUT和角膜敏感性方面,KLEx比FS-LASIK具有显著优势,表明泪膜稳定性更好且神经保留更佳。两种手术在OSDI和泪液分泌试验结果方面产生了相似的结果。这些发现表明,对于术后干眼疾病风险较高的患者,KLEx可能是更优选择。未来的研究应侧重于标准化方案和长期随访,以强化这些结论。